|Table of Contents|

Research progress of immune checkpoint inhibitor therapy-immune-related venous thromboembolic events

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 13
Page:
2546-2552
Research Field:
Publishing date:

Info

Title:
Research progress of immune checkpoint inhibitor therapy-immune-related venous thromboembolic events
Author(s):
LI Huimin; LI Hong; LUO Qin
Department of Respiratory and Neurology,the Affiliated Tumor Hospital of Xinjiang Medical University,Xinjiang Urumqi 830011,China.
Keywords:
cancer-associated venous thromboembolism; immune checkpoint inhibitors; immune-related adverse events; anticoagulant therapy
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.13.034
Abstract:
VTE,which includes pulmonary thromboembolism (PE) and deep vein thrombosis (DVT),is the second leading cause of death in cancer patients.Many factors can contribute to the increased risk of thrombosis in patients with cancer,especially treatment-related factors,such as surgery,chemotherapy,and more recently anti-angiogenesis agents.Currently,immune checkpoint inhibitors (ICIs) impair tumor immune-escape mechanisms by targeting programmed cell death 1 or its ligand (PD-1/PD-L1) or cytotoxic T-lymphocyte antigen 4 (CTLA-4).The most common ICIs adverse effects are immune-related adverse events (irAEs) that may potentially affect any organs or systems,including skin,thyroid,gastrointestinal,or hematological disorders such as autoimmune hemolytic anemia or thrombocytopenia.However,thrombosis had not been commonly reported as irAEs in landmark phase III clinical trials of ICIs.Therefore,there is a great need for clinicians to improve their understanding of ICIs-associated VTE events.This article reviews the VTE incidence,risk factors,its potential pathogenesis and management principles of VTE caused by ICIs treatment,thus guiding the implementation of clinical VTE prevention and treatment for patients on ICIs.

References:

［1］ GRILZ E,POSCH F,NOPP S,et al.Relative risk of arterial and venous thromboembolism in persons with cancer vs.persons without cancer-a nationwide analysis［J］.Eur Heart J，2021,42(23):2299-2307.
［2］ SINGH G,RATHI AK,SINGH K,et al.Venous thromboembolism in cancer patients-magnitude of problem,approach,and management［J］.Indian J Cancer，2017,54(1):308-312.
［3］ RONDON AMR,KROONE C,KAPTEIJN MY,et al.Role of tissue factor in tumor progression and cancer-associated thrombosis［J］.Semin Thromb Hemost，2019,45(4):396-412.
［4］ KHORANA AA,FRANCIS CW,CULAKOVA E,et al.Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy［J］.J Thromb Haemost，2007,5(3):632-634.
［5］ DEBBIE JIANG MD,ALFRED LAN LEE MD.Thrombotic risk from chemotherapy and other cancer therapies［J］.Cancer Treat Res，2019,179:87-101.
［6］ GIUSTOZZI M,CURCIO A,WEIJS B,et al.Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer［J］.Thromb Haemost，2020,120(5):847-856.
［7］ HASLAM A,PRASAD V.Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs［J］.JAMA Netw Open，2019,2(5):1-9.
［8］ VADDEPALLY RK,KHAREL P,PANDEY R,et al.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence［J］.Cancers (Basel)，2020，12(3):1-19.
［9］ BAGCHI S,YUAN R,ENGLEMAN EG.Immune checkpoint inhibitors for the treatment of cancer:clinical impact and mechanisms of response and resistance［J］.Annu Rev Pathol，2021,16:223-249.
［10］ KARTOLO A,YEUNG C,MOFFAT GT,et al.Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors［J］.Immunotherapy，2022,14(1):23-30.
［11］ WANG TF,KHORANA AA,CARRIAER M.Thrombotic complications associated with immune checkpoint inhibitors［J］.Cancers (Basel)，2021,13(18):1-12.
［12］ KUNIMASA K,NISHINO K,KIMURA M,et al.Pembrolizumab-induced acute thrombosis:A case report［J］.Medicine (Baltimore)，2018,97(20):1-3.
［13］ TSUKAMOTO J,MONTEIRO M,VALE S,et al.Thromboembolic events related to treatment with checkpoint inhibitors:report of two cases［J］.Case Rep Oncol，2018，11(3):648-653.
［14］ ABBAS W,DIXIT G,RAO RR,et al.Immunotherapy-induced acute pulmonary thromboembolism:A case report［J］.South Asian J Cancer，2019，8(3):172-182.
［15］ HERBST RS,BAAS P,KIM DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial［J］.Lancet，2016,387(10027):1540-1550.
［16］ CARBONE DP,RECK M,PAZ-ARES L,et al.First-line nivolumab in stage IV or recurrent non-small-cell lung cancer［J］.N Engl J Med，2017,376(25):2415-2426.
［17］ SOCINSKI MA,JOTTE RM,CAPPUZZO F,et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC［J］.N Engl J Med，2018,378(24):2288-2301.
［18］ HELLMANN MD,PAZ-ARES L,BERNABE CARO R,et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer［J］.N Engl J Med，2019,381(21):2020-2031.
［19］ TARHINI AA,LEE SJ,HODI FS,et al.Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma:North American Intergroup E1609［J］.J Clin Oncol，2020,38(6):567-575.
［20］ SOLINAS C,SABA L,SGANZERLA P,et al.Venous and arterial thromboembolic events with immune checkpoint inhibitors:A systematic review［J］.Thromb Res，2020,196:444-453.
［21］ PETRELLI F,SOLINAS C.Reply to the letter to the editor ' Reply to Solinas et al,venous and arterial thromboembolic events with immune checkpoint inhibitors:A systematic review' by Frere et al［J］.Thromb Res，2021,208:217-218.
［22］ GOEL A,KHORANA A,KARTIKA T,et al.Assessing the risk of thromboembolism in cancer patients receiving immunotherapy［J］.Eur J Haematol，2022,108(4):271-277.
［23］ SUSSMAN TA,LI H,HOBBS B,et al.Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival［J］.J Immunother Cancer，2021,9(1):1-8.
［24］ DESCHENES-SIMARD X,RICHARD C,GALLAND L,et al.Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer:A retrospective multicentric cohort study［J］.Thromb Res，2021,205:29-39.
［25］ ROOPKUMAR J,SWAIDANI S,KIM AS,et al.Increased incidence of venous thromboembolism with cancer immunotherapy［J］.Med (N Y)，2021,2(4):423-434.
［26］ GUVEN DC,AKSUN MS,SAHIN TK,et al.Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy［J］.Support Care Cancer，2021,29(9):5417-5423.
［27］ GONG J,DROBNI ZD,ALVIl RM,et al.Immune checkpoint inhibitors for cancer and venous thromboembolic events［J］.Eur J Cancer，2021,158:99-110.
［28］ MOIK F,CHAN WE,WIEDEMANN S,et al.Incidence,risk factors,and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy［J］.Blood，2021,137(12):1669-1678.
［29］ GUTIERREZ-SAINZ L,MARTINEZ-MARIN V,VINAL D,et al.Incidence of venous thromboembolic events in cancer patients receiving immunotherapy:a single-institution experience［J］.Clin Transl Oncol，2021，23(6):1245-1252.
［30］ CARRIER M,KHORANA AA,ZWICKER JI,et al.Venous thromboembolism in cancer clinical trials:recommendation for standardized reporting and analysis［J］.J Thromb Haemost，2012,10(12):2599-2601.
［31］ BAR J,MARKEL G,GOTTFRIED T,et al.Acute vascular events as a possibly related adverse event of immunotherapy:a single-institute retrospective study［J］.Eur J Cancer，2019,120:122-131.
［32］ ICHT O,DARZI N,SHIMONY S,et al.Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors［J］.J Thromb Haemost，2021,19(5):1250-1258.
［33］ MULDER FI,HORVATH-PUHO E,VAN ES N,et al.Venous thromboembolism in cancer patients:a population-based cohort study［J］.Blood，2021,137(14):1959-1969.
［34］ LI H,SUN X,SUN D,et al.Thromboembolic events associated with immune checkpoint inhibitors:A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database［J］.Int Immunopharmacol，2021,98:1-7.
［35］ KARTOLO A,YEUNG C,MOFFAT GT,et al.Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors［J］.Immunotherapy，2022,14(1):23-30.
［36］ RONDON AMR,KROONE C,KAPTEIJN MY,et al.Role of tissue factor in tumor progression and cancer-associated thrombosis［J］.Semin Thromb Hemost，2019，45(4):396-412.
［37］ HORIO Y,TAKAMATSU K,TAMANOI D,et al.Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient［J］.Eur J Immunol，2018,48(10):1764-1767.
［38］ SATO R,IMAMURA K,SAKATA S,et al.Disorder of coagulation-fibrinolysis system:An emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies［J］.J Clin Med，2019，8(6):1-22.
［39］ COCHAIN C,CHAUDHARI SM,KOCH M,et al.Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice［J］.PLoS One，2014,9(4):1-10.
［40］ BU DX,TARRIO M,MAGANTO-GARCIA E,et al.Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation［J］.Arterioscler Thromb Vasc Biol，2011，31(5):1100-1107.
［41］ SACCHI A,GRASSI G,NOTARI S,et al.Expansion of myeloid derived suppressor cells contributes to platelet activation by l-arginine deprivation during SARS-CoV-2 infection［J］.Cells，2021,10(8):1-7.
［42］ ALFARO C,TEIJEIRA A,ONATE C,et al.Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)［J］.Clin Cancer Res，2016,22(15):3924-3936.
［43］ KEY NS,KHORANA AA,KUDERER NM,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:ASCO clinical practice guideline update［J］.J Clin Oncol，2020,38(5):496-520.
［44］ KEWAN T,KO T,FLORES M,et al.Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors［J］.Eur J Haematol，2021，106(5):682-688.
［45］ CARRIER M,ABOU-NASSAR K,MALLICK R,et al.Apixaban to prevent venous thromboembolism in patients with cancer［J］.N Engl J Med，2019,380(8):711-719.
［46］ KHORANA AA,SOFF GA,KAKKAR AK,et al.Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer［J］.N Engl J Med，2019,380(8):720-728.
［47］ KHORANA AA,NOBLE S,LEE AYY,et al.Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism:guidance from the SSC of the ISTH［J］.J Thromb Haemost，2018,16(9):1891-1894.
［48］ 马军,秦叔逵,吴一龙,等.肿瘤相关静脉血栓栓塞症预防与治疗指南（2019版）［J］.中国肿瘤临床,2019,46(13):653-660. MA J,QIN SK,WU YL,et al.Guidelines for the prevention and treatment of tumor-associated venous thromboembolism (2019 edition)［J］.Chin J Clin Oncol,2019,46(13):653-660.
［49］ MAO Z,JIA X,JIANG P,et al.Effect of concomitant use of analgesics on prognosis in patients treated with immune checkpoint inhibitors:A systematic review and Meta-analysis［J］.Front Immunol，2022,13:1-12.

Memo

Memo:
National Natural Science Foundation of China(No.81760014）；国家自然科学基金（编号：81760014）；自治区科技支疆项目（编号：2019E0281）；新疆维吾尔自治区自然科学基金资助项目（编号：2022D01D74）
Last Update: 2023-05-31